Resources

Your selections:

Clear all

Show Filters

We found 233 resources that match your search.

.zip files contains Presentation to HPTN/IMPAACT Annual Meeting on Expedited Reporting to DAIDS and DAERS refresher course Expedited reporting via DAERS - Case Study

Document Date:

.zip file contains: Presentation to HVTN Annual Meeting on Expedited Reporting to DAIDS and DAERS refresher course; Expedited reporting via DAERS - Case Study

Document Date:

Guidance and requirements for daids-supported research involving recombinant DNA.

Document Date:

Document Date:

.zip files contains: Safety training presentation on expedited reporting to DAIDS and a refresher on DAERS Case study handout Meeting for HPTN and IMPAACT networks was held June 2016.

Document Date:

List of IND protocols having CRF/Pharmacy records that will not be stored by DAIDS.

Document Date:

Instructions for the transfer of case report forms, (CRF) and pharmacy records to the DAIDS regulatory support center, (DAIDS RSC).

Document Date:

Informed Consent documents are in the process of being updated to be compliant with the revised Common Rule.

Document Date:

DAIDS protocol specific informed consent template—general use.

Document Date:

Informed Consent documents are in the process of being updated to be compliant with the revised Common Rule.

Document Date:

Document Date:

ISENTRESS is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated: * In combination with other antiretroviral agents for the treatment of HIV-1 infection in patients 4 weeks of age and older (1). The use of other active agents with ISENTRESS is associated with…

Document Date:

Document Date:

Isoniazid is an antibacterial available as 100 mg and 300 mg tablets for oral administration. Each tablet also contains as inactive ingredients: colloidal silicon dioxide, lactose monohydrate, pregelatinized starch (corn), povidone and stearic acid.

Document Date:

The following side effects have also been associated with use of lamivudine: If you are infected with both Hepatitis B and HIV, you should be aware that your liver function tests may increase, and symptoms associated with hepatitis (an acute inflammation of the liver) may worsen if lamivudine is…

Document Date:

HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV).

Document Date:

Document Date:

LIVALO is a HMG-CoA reductase inhibitor indicated for: Patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase…

Document Date:

Letter of amendment flowchart for Protocol Teams.

Document Date:

The following serious side effects are associated with the use of lopinavir/ritonavir: Abnormal heart rhythm and electrocardiogram (EKG) changes. These changes can lead to serious heart problems. Your risk for these problems may be higher if you: Already have a history of abnormal heart rhythm or…

Document Date: